396 related articles for article (PubMed ID: 10379420)
1. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.
DeVane CL
Cell Mol Neurobiol; 1999 Aug; 19(4):443-66. PubMed ID: 10379420
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
Preskorn SH
Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
Sánchez C; Hyttel J
Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
[TBL] [Abstract][Full Text] [Related]
5. Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology.
Goodnick PJ; Goldstein BJ
J Psychopharmacol; 1998; 12(3 Suppl B):S5-20. PubMed ID: 9808077
[TBL] [Abstract][Full Text] [Related]
6. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
[TBL] [Abstract][Full Text] [Related]
7. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Baumann P; Rochat B
Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 1():15-21. PubMed ID: 7622807
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of selective serotonin reuptake inhibitors.
Hiemke C; Härtter S
Pharmacol Ther; 2000 Jan; 85(1):11-28. PubMed ID: 10674711
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of selective serotonin reuptake inhibitors.
van Harten J
Clin Pharmacokinet; 1993 Mar; 24(3):203-20. PubMed ID: 8384945
[TBL] [Abstract][Full Text] [Related]
11. Overview of the pharmacokinetics of fluvoxamine.
van Harten J
Clin Pharmacokinet; 1995; 29 Suppl 1():1-9. PubMed ID: 8846617
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Mandrioli R; Mercolini L; Saracino MA; Raggi MA
Curr Med Chem; 2012; 19(12):1846-63. PubMed ID: 22414078
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
15. The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K
Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
[TBL] [Abstract][Full Text] [Related]
16. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain.
Narita N; Hashimoto K; Tomitaka S; Minabe Y
Eur J Pharmacol; 1996 Jun; 307(1):117-9. PubMed ID: 8831113
[TBL] [Abstract][Full Text] [Related]
17. [Paroxetine (paxil): use in clinical practice].
Litvintsev SV; Reznik AM; Arbuzov AL; Mironychev GN
Voen Med Zh; 2002 Jan; 323(1):35-9. PubMed ID: 11881199
[No Abstract] [Full Text] [Related]
18. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Finley PR
Ann Pharmacother; 1994 Dec; 28(12):1359-69. PubMed ID: 7696728
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
20. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses.
Taylor D
Br J Psychiatry; 1995 Nov; 167(5):575-80. PubMed ID: 8564311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
